Status:
COMPLETED
Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients
Lead Sponsor:
Kidney Cancer Research Bureau
Conditions:
Metastatic Renal Cell Carcinoma
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. The role of capecitabine in treatment of metastatic renal cell carcinom...
Eligibility Criteria
Inclusion
- histologically confirmed non-clear cell renal cell carcinoma
- confirmed metastatic sites
- no chemotherapy in history
Exclusion
- metastases in CNS
- previous targeted therapy
- other tumor
Key Trial Info
Start Date :
September 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2010
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT01182142
Start Date
September 1 2007
End Date
August 1 2010
Last Update
August 24 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Natalia Petenko
Moscow, Russia